RRP is divided into three branches: The Radiotherapy Development Branch (RDB), the Clinical Radiation Oncology Branch (CROB) and the Molecular Radiation Therapeutics Branch (MRTB).
The primary responsibility of RRP is to the grantees and contractors of NCI and NIH. In 2009, RRP administered 212 awarded grants, primarily through the Radiotherapy Development Branch. In addition to grants management and related duties, RRP program staff advise on, and act as reviewers for grants and contracts submitted to the Department of Defense and BARDA and consult on radiation issues with program staff in NIAID.
The CROB manages a grant portfolio dealing with clinical and translational research in radiation oncology as well as the technical and physical aspects of radiation research and development. In addition to managing the RRP grant portfolio a substantial effort is devoted to supporting NCI, NIH, DHHS and government-wide activities such as technology development and assessment and comparative effectiveness research.
The MRTB is an RRP in-house laboratory program that serves as a focal point for collaborations with the Developmental Therapeutics Program (DTP) and Cancer Therapy Evaluation Program (CTEP) in DCTD, investigators in the Radiation Biology and Radiation Oncology Branches in the Center for Cancer Research (CCR), and university and industry collaborators specifically addressing research and development needs in combined modality therapy using radiation.